Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32342878.
- Also identified by DOI 10.1016/j.radonc.2020.04.010 and PMC identifier 7194719.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
As of April 6, 2020, there are over 1,200,000 reported cases and 70,000 deaths worldwide due to COVID-19, the disease caused by the SARS-CoV-2 virus, and these numbers rise exponentially by the day [1]. According to the Centers for Disease Control (CDC), the most effective means of minimizing the spread of the virus is through reducing interactions between individuals [2]. We performed a review of the literature, as well as national and international treatment guidelines, seeking data in support of the RADS principle (Remote visits, Avoid radiation, Defer radiation, Shorten radiation) [3] as it applies to gastrointestinal cancers. The purpose of the present work is to guide radiation oncologists managing patients with gastrointestinal cancers during the COVID-19 crisis in order to maintain the safety of our patients, while minimizing the impact of the pandemic on cancer outcomes.
Medical subject headings
- Betacoronavirus
- Coronavirus Infections
- Gastrointestinal Neoplasms
- Pandemics
- Pneumonia, Viral